









Markets
/
Stocks
/
nasdaq-abp
/

ABPRO Holdings Inc

ABP

1.500USD

0.0000.00%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

4.01MMarket Cap

LossP/E TTM



ABPRO Holdings Inc

1.500

0.0000.00%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of ABPRO Holdings Inc

Currency: USD Updated: 2026-02-06

Key Insights

ABPRO Holdings Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 221 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 2.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ABPRO Holdings Inc's Score

Industry at a Glance

Industry Ranking

221 / 392

Overall Ranking

459 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

ABPRO Holdings Inc Highlights

StrengthsRisks

Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).

Growing

The company is in a growing phase, with the latest annual income totaling USD 183.00K.

Overvalued

The company’s latest PE is -0.06, at a high 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 20.08K shares of this stock.

Analyst Rating

Based on 1 analysts

Hold

Current Rating

2.000

Target Price

+954.85%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of ABPRO Holdings Inc is 6.32, ranking 267 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.32

Change



Financials

3.39

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.49

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.16

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.55

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

ABPRO Holdings Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of ABPRO Holdings Inc is 8.14, ranking 60 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.06, which is -100.00% below the recent high of 0.00 and -132511.74% above the recent low of -82.48.

Score

Industry at a Glance

Previous score

8.14

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 221/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for ABPRO Holdings Inc. The Biotechnology & Medical Research industry's average is 8.05. The average price target is 2.00, with a high of 2.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Hold

Current Rating

2.000

Target Price

+954.85%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

ABPRO Holdings Inc

ABP

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of ABPRO Holdings Inc is 5.27, ranking 325 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.26 and the support level at 0.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.48

Change

-0.21

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.080

Sell

RSI(14)

21.382

Sell

STOCH(KDJ)(9,3,3)

4.682

Oversold

ATR(14)

0.375

Low Volatility

CCI(14)

-114.100

Sell

Williams %R

97.030

Oversold

TRIX(12,20)

-3.322

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.736

Sell

MA10

1.915

Sell

MA20

2.691

Sell

MA50

4.255

Sell

MA100

5.184

Sell

MA200

6.091

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Abpro Bio International Inc

550.24K

Chan (Ian)

275.51K

-10.67%

Atlantic Coastal Acquisition Management II LLC

116.08K

-0.00%

Yorkville Advisors Global, LP.

28.61K

The Vanguard Group, Inc.

Star Investors

20.91K

+678.81%

Suk (Jin Wook)

7.07K

Geode Capital Management, L.L.C.

6.79K

+3.69%

XTX Markets LLC

2.95K

Polar Asset Management Partners Inc.

2.92K

AQR Capital Management, LLC

2.92K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of ABPRO Holdings Inc is 1.14, ranking 346 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.02. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.